Mogamulizumab (Poteligeo®). HTA ID: 20061

Assessment Status Assessment Process Complete
HTA ID 20061
Drug Mogamulizumab
Brand Poteligeo®
Indication For the treatment of adult patients with mycosis fungoides or Sézary syndrome who have received at least one prior systemic therapy.
Assessment Process
Rapid review commissioned 21/12/2020
Rapid review completed 21/01/2021
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of mogamulizumab (Poteligeo®) compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 27/01/2021
Pre-submission consultation with Applicant 23/03/2021
Full submission received from Applicant 07/10/2021
Preliminary review sent to Applicant 22/02/2022
NCPE assessment re-commenced 23/03/2022
Follow-up to preliminary review sent to Applicant 07/04/2022
NCPE assessment re-commenced 19/04/2022
Factual accuracy sent to applicant 17/06/2022
NCPE assessment re-commenced 24/06/2022
NCPE assessment completed 09/08/2022
NCPE assessment outcome The NCPE recommends that mogamulizumab (Poteligeo®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments.*

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.